Profile data is unavailable for this security.
About the company
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
- Revenue in SEK (TTM)0.00
- Net income in SEK-258.05m
- Incorporated2003
- Employees24.00
- LocationXSpray Pharma AB (publ)Rasundavagen 12SOLNA 169 67SwedenSWE
- Phone+46 87303700
- Websitehttps://xspraypharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcticzymes Technologies ASA | 108.08m | 7.00m | 668.37m | 68.00 | 95.84 | 2.10 | 51.51 | 6.18 | 0.1367 | 0.1367 | 2.10 | 6.24 | 0.3199 | 0.45 | 1.93 | 1,591,059.00 | 2.07 | 15.58 | 2.19 | 17.22 | 93.99 | 96.69 | 6.47 | 33.23 | 14.95 | -- | 0.0273 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| Thor Medical ASA | 0.00 | -18.54m | 688.63m | 1.00 | -- | 2.65 | -- | -- | -0.0873 | 0.021 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -9.82 | -79.17 | -10.54 | -113.94 | -- | -- | -- | -- | -- | -- | 0.0035 | -- | -- | -- | -- | -- | -- | -- |
| Nykode Therapeutics ASA | 67.98m | -419.28m | 905.85m | 179.00 | -- | 0.5386 | -- | 13.33 | -1.35 | -1.35 | 0.2128 | 5.16 | 0.0333 | -- | 1.59 | 393,326.30 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Intellego Technologies AB | 231.25m | 82.86m | 1.05bn | 62.00 | 12.15 | 4.49 | 11.56 | 4.53 | 3.03 | 3.03 | 8.50 | 8.20 | 0.8298 | 4.24 | 2.45 | 3,729,807.00 | 29.74 | -- | 37.90 | -- | 68.61 | -- | 35.83 | -- | 1.88 | 8.84 | 0.1532 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -258.05m | 1.28bn | 24.00 | -- | 2.42 | -- | -- | -7.81 | -7.81 | 0.00 | 17.14 | 0.00 | -- | -- | 0.00 | -37.64 | -18.38 | -40.48 | -19.26 | -- | -- | -- | -- | 1.51 | -- | 0.0543 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Diamyd Medical AB | 131.00k | -151.85m | 1.28bn | 28.00 | -- | 8.68 | -- | 9,801.27 | -1.60 | -1.60 | 0.0014 | 1.46 | 0.0006 | -- | 3.20 | 4,678.57 | -71.82 | -34.32 | -83.67 | -38.45 | -10,083.21 | -3,111.20 | -115,916.00 | -17,499.13 | -- | -- | 0.1737 | -- | -76.19 | -39.23 | -30.82 | -- | -- | -- |
| Nightingale Health Oyj | 50.49m | -202.32m | 1.32bn | 86.00 | -- | 2.05 | -- | 26.07 | -0.2895 | -0.2895 | 0.0722 | 1.37 | 0.0441 | 2.33 | 3.46 | 50,674.42 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.90 | -400.71 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
| Nanoform Finland Oyj | 26.58m | -251.02m | 1.34bn | 174.00 | -- | 1.63 | -- | 50.40 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Cereno Scientific AB | 0.00 | -69.48m | 1.38bn | 5.00 | -- | 5.44 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Solar Foods Oyj | 200.66k | -123.85m | 1.44bn | 40.00 | -- | 4.40 | -- | 7,184.60 | -0.4438 | -0.4438 | 0.0007 | 1.15 | 0.0004 | -- | 0.0049 | 558.71 | -21.32 | -- | -24.11 | -- | 20,183.14 | -- | -61,719.29 | -- | -- | -2.71 | 0.4266 | -- | -- | -- | -66.44 | -- | -- | -- |
| Vicore Pharma Holding AB | 104.24m | -196.45m | 1.83bn | 29.00 | -- | 2.30 | -- | 17.51 | -1.72 | -1.72 | 0.9135 | 3.38 | 0.2045 | -- | 43.73 | 4,343,459.00 | -38.54 | -58.65 | -41.49 | -65.58 | -- | -- | -188.45 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2023 | 3.12m | 9.99% |
| Tredje AP-fondenas of 31 Dec 2023 | 1.17m | 3.73% |
| Andra AP-fondenas of 31 Dec 2023 | 933.48k | 2.99% |
| Teknik Innovation Norden Fonder ABas of 31 Dec 2022 | 605.47k | 1.94% |
| C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Dec 2023 | 231.20k | 0.74% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 213.31k | 0.68% |
| SEB Investment Management ABas of 31 Oct 2024 | 153.72k | 0.49% |
| Mandarine Gestion SAas of 29 Feb 2024 | 150.00k | 0.48% |
| FCG Fonder ABas of 31 Oct 2024 | 114.81k | 0.37% |
| Skandia Investment Management ABas of 30 Sep 2024 | 18.51k | 0.06% |
